.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
QuintilesIMS
Colorcon
Accenture
Express Scripts
Boehringer Ingelheim
UBS
Chubb
Johnson and Johnson
Novartis

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,105,626

« Back to Dashboard

Which drugs does patent 8,105,626 protect, and when does it expire?


Patent 8,105,626 protects DEXILANT and is included in one NDA. There have been two Paragraph IV challenges on Dexilant.

Protection for DEXILANT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,105,626

Title:Granules containing acid-unstable chemical in large amount
Abstract: It is intended to provide preparations such as capsules containing an acid-unstable medicament (in particular, a benzimidazole compound having an antiulcer effect, etc.) at a high concentration which are prepared by using about 12% by weight or more (based on the total granules) of the acid-unstable chemical and blending a basic inorganic salt therewith to give granules of about 600 .mu.m or more in the average particle size.
Inventor(s): Shimizu; Toshihiro (Itami, JP), Nakano; Yoshinori (Takarazuka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:10/492,690
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms UsaDEXILANTdexlansoprazoleCAPSULE, DELAYED RELEASE;ORAL022287-001Jan 30, 2009RXYesNo► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaDEXILANTdexlansoprazoleCAPSULE, DELAYED RELEASE;ORAL022287-002Jan 30, 2009ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,105,626

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2001-319444Oct 17, 2001
PCT Information
PCT FiledOctober 16, 2002PCT Application Number:PCT/JP02/10720
PCT Publication Date:April 24, 2003PCT Publication Number: WO03/032953

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Colorcon
McKinsey
Merck
Federal Trade Commission
Julphar
Accenture
UBS
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot